Vaccines are a promising but still experimental treatment for melanoma. They are intended to stimulate immune responses against melanoma and by so doing, increase resistance against and slow the progression of this cancer. Key requirements for vaccines to be effective are that they contain antigens that can stimulate tumor-protective immune responses and that some of these antigens are present on the tumor to be treated. Unfortunately, these antigens are still not known. To circumvent this problem, polyvalent vaccines can be constructed containing a broad array of melanoma-associated antigens. Several strategies are available to construct such polyvalent vaccines; each has advantages and disadvantages. Clinical trials have shown that vaccines are safe to use and have much less toxicity than current therapy for melanoma. Vaccines can stimulate both antibody and T-cell responses against melanoma, with the type of response induced, its frequency, and its magnitude depending on the vaccine and the adjuvant agent used. A growing body of evidence suggests that vaccines can be clinically effective. This evidence includes correlations between vaccineinduced antibody or T-cell responses and improved clinical outcome, clearance of melanoma markers from the circulation, improved survival compared to historical controls, and most convincingly, two randomized trials in which the recurrence-free survival of vaccine-treated patients was significantly longer than that of control groups.
There is an urgent need for better treatments for melanoma. No therapy prolongs survival in patients with widely disseminated disease. Only one treatment is approved by the US Food and Drug Administration (FDA) for patients with resected disease at high risk of progression-interferon alfa-2b (Intron A)-and it has limited effectiveness as well as frequent and potentially severe side effects.
Vaccines are receiving increasing attention as a still-experimental treatment for this cancer. Theoretically, vaccines should permit the selective and safe destruction of melanoma cells. The rationale for believing that melanoma vaccines can be effective, the relative advantages and disadvantages of the different strategies used to construct melanoma vaccines, and the results obtained to date are summarized below.
Rationale for a Melanoma Vaccine
The progression of melanoma is influenced by immune factors, and stimulation of these factors with vaccines can increase resistance to this cancer.[ 1] The two most compelling observations that support this belief are:
(1) In vivo mechanisms can kill melanoma cells selectively, without harming normal melanocytes. This is evidenced by the partial regression of melanoma in 15% to 20% of primary lesions,[2,3] and by the rare but dramatic, spontaneous, and complete regression of advanced tumors. Partial regression in primary melanomas is actually visible as areas of white depigmentation within the tumor (Figure 1). The white areas are due to the destruction of melanoma cells. As regression occurs spontaneously without any treatment, it clearly indicates that humans possess protective mechanisms that have the ability to destroy melanoma cells. These defense mechanisms are very selective, as they destroy melanoma cells without harming adjuvant normal melanocytes. This is evident from the skin adjacent to areas of regression retaining its normal pigmentation. The selectivity of this process, which destroys malignant melanocytes without harming normal melanocytes, indicates it is mediated by immune mechanisms, as only the immune system has the exquisite ability to recognize the difference between malignant and normal cells. Stimulating these immune defenses is the purpose of vaccines.
(2) Vaccines can markedly increase resistance to melanoma-at least in animals. Murine B16 melanoma is invariably fatal when injected into mice, killing all within 6 to 8 weeks. By contrast, almost all mice preimmunized to vaccines against melanoma can survive, as illustrated in Figure 2. The protection is specific for melanoma. Melanoma vaccine- immunized mice are not protected against an unrelated tumor. This specificity indicates that the protective mechanisms stimulated by vaccine treatment are immunologic in nature.
Tumor Regression vs Absence of Progression
An incidental observation in mice has an important implication for the clinical impact of vaccine treatment in humans and the end point of such trials. That is, vaccine-treated mice can live in an apparent state of good health for months while bearing large tumors that would invariably and rapidly kill nonimmunized mice. This is apparent from examining vaccinetreated mice that survive challenge with lethal doses of melanoma cells. Such mice appear clinically healthy, gain weight, and have no evidence of tumor. Yet autopsy performed months after tumor challenge reveals that many of the animals have very large melanomas in their internal organs, of a size that would kill nonimmunized mice within days.
Thus, the degree of resistance induced by vaccine treatment in these animals was insufficient to cause tumor regression, but was sufficient to prevent tumors from continuing to progress and kill the animals. The implication of this observation extended to humans is that vaccine treatment may improve survival by slowing tu- mor progression rather than by causing tumor regression. It implies that the key end point in evaluating vaccine clinical trials should be absence of tumor progression rather than the conventional end point of tumor regression.
Additional observations supporting the idea that immune mechanisms play an important role in slowing the progression of melanoma include the presence on melanoma cells of antigens that are either unique or present in larger amounts than on normal melanocytes, the ability of these antigens to stimulate antibody and/or T-cell responses in patients with melanoma, and the infiltration of lymphocytes into melanoma nodules of vaccinetreated patients. Investigators have noted correlations between the presence of these immune responses and an improved clinical outcome, indicating that these responses can play an active role in controlling the progression of melanoma.[7-11]
Thus, there are theoretical reasons for believing that vaccines can increase resistance to melanoma and practical observations that they actually do so in animals. The challenge is to develop vaccines that will be as effective in humans.
What Is Required for Melanoma Vaccines to Be Effective
Melanoma vaccines are intended to stimulate patients' immune systems to react more effectively against their own melanoma and, by so doing, destroy the tumor or slow its progression. To do so, the vaccines must satisfy several requirements. The two most important are:
(1) The vaccine must contain antigen(s) that can stimulate tumorprotective immune responses.
(2) Some of these antigens must be present on a patient's own tumor; otherwise, the vaccine-induced immune responses will be unable to recognize and attack the tumor.
A number of other requirements must be satisfied for a vaccine to be effective and practical to use, as discussed subsequently. Vaccines must also be safe to use, their composition well characterized, and their manufacture reproducible. To retain their potential to provide cost-effective therapy, the vaccines should be relatively simple to prepare and administer.
Challenges in the Design of Melanoma Vaccines
Unfortunately, there are major problems satisfying the two major requirements described above.
• Selection of Antigens Used to Prepare the Vaccine—This is the most critical issue in preparing a cancer vaccine, as the vaccine must contain antigen that can stimulate tumor-protective immunity or it will not work. Although many antigens associated with melanoma have been identified, we do not know which ones are appropriate for this purpose. Establishing this ability is arduous, requiring a large-scale phase III randomized clinical trial of each antigen, to demonstrate objectively whether it slows the progression of melanoma. Taking into account the number of candidate antigens, the size and expense of phase III trials, and the limited number of melanoma patients available, it is not possible to conduct such trials for every currently known melanoma-associated antigen and for new ones that will be discovered. Thus, it will be difficult to find out which melanoma antigens actually stimulate protective immunity against this cancer and should be used to construct vaccines.
• Antigenic Heterogeneity—Another complication in selecting antigens to construct melanoma vaccines is that some of the unknown antigen(s) that stimulate protective immunity must also be expressed by the tumor to be treated. Unfortunately, the expression of tumor antigens by melanoma cells is heterogeneous. It varies between melanomas in different individuals, between different tumor nodules in the same individual, and between different melanoma cells within the same tumor nodule.[12-14] Furthermore, the actual antigens expressed by residual melanoma cells in a patient at the time treatment is instituted cannot be known. A solution suggested to circumvent this problem is to prepare autologous vaccines from a patient's own tumor. However, this would not resolve the problem, because there is no assurance that the antigens present in the tumor tissue used to prepare the vaccine will be the same as those in the residual tumor(s) that need treatment.
• Antigen Modulation—The pattern of antigens expressed by tumor cells can change during tumor progression.[ 15] This reflects the changes that occur in tumors as they metastasize, in part due to immunologic pressures on the tumor. Vaccine-induced immune responses destroy tumor cells bearing the targeted antigen(s), resulting in the selection and expansion of surviving cells that lack these targets and that now resist the action of the vaccine.
Thus, it is unknown which antigens should be used to construct melanoma vaccines, whether these are expressed by the tumor to be treated, or whether they will still be there once treatment begins.
• HLA Restriction—Some immune responses that are critical in tumorprotective immunity, such as antigenspecific CD8+ and CD4+ T-cell responses, are human leukocyte antigen (HLA) restricted. As a consequence, each vaccine peptide antigen will induce these responses only in patients who have the particular type of HLA molecule that can bind that peptide. As there are a large number of HLA molecules, and as the expression of each varies from individual to individual, only a minority of patients express the HLA molecule required to bind a particular peptide. Even the most common HLA molecule (HLA-A0201) is expressed by only 40% of white individuals, the population most at risk for melanoma. Many HLA molecules are expressed by only a small percentage of patients to be treated.
Thus, even if one could identify a peptide capable of stimulating a tumor- protective cellular response, a vaccine made from that peptide would at best be effective in less than half of the population at risk for melanoma. Because of the variable expression of antigens on melanoma cells, the proportion of patients who can theoretically benefit from vaccines prepared from any one antigen is even smaller.
• HLA-Unrelated Heterogeneity in Immune Responses—Independent of HLA restriction, investigators have also found heterogeneity in the ability of different patients to develop cellular immune responses to antigens.[ 16] That is, patients who express the same HLA phenotype and who are immunized identically to the same antigen can vary in their ability to develop a CD8+ T-cell response to that antigen. This is not due to lack of immune competence by the patients, as patients who do not respond to one peptide will respond well to another peptide presented by the same HLA molecule. Similar heterogeneity is seen in the ability of individuals to develop antibody responses. This heterogeneity further limits the proportion of patients who can develop effective antitumor immune responses to any single antigen.
• Number of Antigens Required to Induce Effective Protective Immunity—It is unknown whether clinically effective tumor-protective immunity in humans can be induced by immunization to a single antigen or whether responses against multiple antigens are required for cancer cells to be killed. Even if immune responses to a single antigen can kill melanoma cells, stimulating responses to multiple antigens should do so more effectively. Thus, the larger the number of antigens in a vaccine, the better it should work. However, there is a price to be paid for increasing the number of antigens in a vaccine, as described below.
1. Bystryn JC. Shapiro RL, Oratz R: Cancer vaccines: Clinical applications: Partially purified tumor antigen vaccines, in DeVita V, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer, 2nd ed, pp 668-679. Philadelphia, JB Lippincott, 1995.
2. Gromet MA, Epstein WL, Blois MS: The regressing thin melanoma. A distinctive lesson with metastatic potential. Cancer 42:2282- 2292, 1978.
3. Balso M, Schiavon M, Cicogna PA, et al: Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast Reconstr Surg 90:1073-1076, 1992.
4. Kopf AW: Host defense against melanoma. Hosp Pract 6:116, 1971.
5. Bystryn J-C: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens. J Immunol 120:96-101, 1978.
6. Oratz R, Cockerall C, Speyer JL, et al: Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod 8:355-358, 1989.
7. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998.
8. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
9. Miller K, Abeless G, Oratz R, et al: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495- 502, 1995.
10. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, et al: Vaccine-induced CD8+ T cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 9:657-662, 2003.
11. Jäger E, Gnjatic S, Nagata Y, et al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO- 1+ cancers. Proc Natl Acad Sci 97:12198- 12203, 2000.
12. Albino AP, Lloyd KO, Houghton AN, et al: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 154:1764-1778, 1981.
13. Bystryn JC, Bernstein P, Liu P, et al: Immunophenotype of human melanoma cells in different metastases. Cancer Res 45:1772- 1777, 1985.
14. Yeh MY, Hellstrom I, Hellstrom KE: Clonal variation in expression of a human melanoma antigen defined by monoclonal antibody. J Immunol 126:1312-1317, 1981.
15. Kageshita T, Hirai S, Ono T, et al: Downregulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression. Am J Pathol 154:745- 754, 1999.
16. Reynolds SR, Celis E, Sette A, et al: HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine- treated melanoma patients. J Immunol 161:6970-6976, 1998.
17. Miller K, Abeles G, Oratz R, et al: Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495-502, 1995.
18. Hsueh EC, Essner R, Foshag LJ, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549-4554, 2002.
19. Sosman JA, Unger JM, Liu PY, et al: Adjuvant immunotherapy of resected, intermediate- thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075, 2002.
20. Berd D: M-Vax: An autologous, haptenmodified vaccine for human cancer. Expert Opin Biol Ther 2:335-342, 2002.
21. Wallack MK, Sivanandham M, Balch CM, et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187:69-79, 1998.
22. Hersey P, Coates AS, McCarthy WH, et al: Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 20:4181-4190, 2002.
23. Belli F, Arienti F, Sule-Soso J, et al: Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203, 1997.
24. Abdel-Wahab Z, Weltz C, Hester D, et al: A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80:401-412, 1997.
25. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocytemacrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141-13146, 1998.
26. Moller P, Sun Y, Dorbic T, et al: Vaccine with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br J Cancer 77:1907-1916, 1998.
27. Arienti F, Belli F, Napolitano F, et al: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10:2907-2916, 1999.
28. Marincola FM, Jaffee EM, Hicklin DJ, et al: Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance. Adv Immunol 74:181-273, 2000.
29. Weber J, Sondak VK, Scotland R, et al: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186-200, 2003.
30. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Can Res 7:3012-3024, 2001.
31. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical response in patients with metastatic melanoma to CD34+ progenitor derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001.
32. Lau R, Wang F, Jeffery G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001.
33. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/ C509801. J Clin Oncol 19:2370-2380, 2001.
34. McCaffery M, Yao TJ, Williams L, et al: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2:679-686, 1996.
35. Foon KA, Lutzky K, Baral RN, et al: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18:376- 384, 2000.
36. Van den Eynde BJ, Boon T: Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27:81-86, 1997.
37. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996.
38. Smith JW 2nd, Walker EB, Fox BA, et al: Adjuvant immunization of HLA-A2 positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562-1573, 2003.
39. Ferrone S: Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Ann N Y Acad Sci 690:214-224, 1993.
40. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882-1887, 2001.
41. Applebaum J, Reynolds S, Knispel J, et al: Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst 90:146-149, 1998.
42. Blachere NE, Srivastava PK: Heat shock protein based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 6:349-355, 1995.
43. Belli F, Testori A, Rivoltini L, et al: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 20:4169-4180, 2002.
44. Relyveld EH, Ben-Efraim S: Preparation of vaccines by the action of glutaldehyde on toxins, bacteria, viruses, allergens and cells. Methods Enzymol 93:24-60, 1983.
45. Chang AE, Redman BG, Whitfield JR, et al: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8:1021-1032, 2002.
46. Chapman PB, Morissey DM, Panageas KS, et al: Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res 6:874-879, 2000.
47. Rosenberg SA, Zhai Y, Yang JC, et al: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894-1900, 1998.
48. Steinman RM: Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med 68:106- 166, 2001.
49. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptideor tumor lystae-pulsed dendritic cells. Nat Med 4:328-332, 1998.
50. Oratz R, Shapiro RL, Johnston D, et al: IL-2 liposomes markedly enhance the activity of a polyvalent melanoma vaccine (abstract 1356). Proc Am Soc Clin Oncol 15:436, 1996.
51. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996.
52. Keilholz U, Weber J, Finke JH, et al: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138, 2002.
53. Cui J, Chen D, Oratz R, et al: Induction of cytolytic antibodies to melanoma by immunization to a polyvalent melanoma antigen vaccine. Vaccine Res 3:175-182, 1994.
54. Reynolds SR, Oratz R, Shapiro RL, et al: Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72:972-976, 1997.
55. Maraveyas A, Baban B, Kennard D, et al: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10:817-824, 1999.
56. Scheibenbogen C, Schmittel A, Keilholz U, et al: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275-281, 2000.
57. Chung MH, Gupta RK, Hsueh E, et al: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 21:313-319, 2003.
58. Reynolds SR, Albrecht J, Shapiro RL, et al: Changes in the presence of multiple markers of circulating melanoma cells correlates with clinical outcome in patients with melanoma. Clin Cancer Res 9:1497-1502, 2003.
59. Garbe C, Leiter U, Ellwanger U, et al: Diagnostic value and prognostic significance of protein S-100, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the followup of high-risk melanoma patients. Cancer 97:1737-1745, 2003.
60. Bystryn J-C, Laky D, Shapiro RL, et al: Prolonged survival of vaccine-treated patients with resected stage IV melanoma (abstract 2911). Proc Am Soc Clin Oncol 22:724, 2003.
61. Bystryn J-C, Oratz R, Roses D, et al: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164, 1992.
62. Mitchell MS, Rechtman DJ, Von Eschen KB: A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 6(suppl C):347C, 1995.
63. Nestle FO, Kerl H: Neoplasms of the skin, in Bolognia JL, Jorizzo JL, Rapini R, et al (eds): Dermatology, p 1789. London, Mosby, 2003.
64. Roberts DL, Anstey AV, Barlow RJ, et al: U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 146:7-17, 2002.
65. Livingston PO, Calves MJ, Natoli EJ Jr: Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells. J Immunol 138:1524-1529, 1987.